Quality of life

We work to find innovative solutions that improve the health and quality of life of our patients.

Pain

A significant number of patients have to deal with pathologies involving pain. It is estimated that one in six Spanish people (17%) suffer from chronic pain. At Gebro Pharma we treat nearly five million suffering patients. Pain is also one of the main factors that lead patients to consult primary care services. Keep reading...
Feliben®
SEE SmPC >
Feliben<sup>®</sup>
Diliban®
SEE SmPC >
Diliban<sup>®</sup>
Paxiflas®
SEE SmPC >
Paxiflas<sup>®</sup>
Seractil®
SEE SmPC >
Seractil<sup>®</sup>
Atriscal®
SEE SmPC >
Atriscal<sup>®</sup>

Rheumatology

The history of our company is also part of the history of rheumatology and rheumatoid arthritis in Spain. Our relationship with this branch of Medicine, dates back to 15 years ago,, begins with the arrival of the first injectable methotrexate: Metoject®. This was in 2004 when Methotrexate was only available by mouth in Spain. Keep reading...
Metoject®
SEE SmPC >
Metoject<sup>®</sup>
Metoject Pen®
SEE SmPC >
Metoject Pen<sup>®</sup>
Videsil®
SEE SmPC >
Videsil<sup>®</sup>

Urology

Our passion for urogynaecology celebrates its tenth birthday. With a wide variety of products included in our urological and gynecological portfolio, urogynecology is already part of the DNA of Gebro Pharma.
The urology franchise is one of our strategic pillars and our commitment to uro-gynecological patients ensures it is an area with a long future ahead of it in our company. Keep reading...
Ialuril® Prefill
SEE SmPC >
Ialuril<sup>®</sup> Prefill
Kentera®
SEE SmPC >
Kentera<sup>®</sup>
Tebetane®
SEE SmPC >
Tebetane<sup>®</sup>

Respiratory

In early 2015 Gebro Pharma breathed new air into the market by inaugurating a new therapeutic area: the respiratory area. The franchise opened its doors with a product that assisted patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Tovanor® Breezhaler® arrived and began to tackle a disease that affects more than 10% of the population, and therefore has an enormous socio-health impact. Keep reading...
Tovanor Breezhaler®
SEE SmPC >
Tovanor Breezhaler<sup>®</sup>

Dermatology

Our relationship with dermatology began 15 years ago when we started to treat the hands and skin of patients with psoriasis, a condition that affects 2.3% of the Spanish population.
We are currently helping the lives of patients with psoriasis with two drugs which in turn represent topical and systemic treatments. Keep reading...
Metoject®
SEE SmPC >
Metoject<sup>®</sup>
Metoject Pen®
SEE SmPC >
Metoject Pen<sup>®</sup>
Cortitape®
SEE SmPC >
Cortitape<sup>®</sup>

Hospital Unit

With the line of hospital products our responsibility for the care of patients is not only therapeutic. It is also social. That is why we focus our activity on hospital medicines for oncology, neurosurgery, urology and drug dependence. The national health system offers the possibility of exclusive and differentiated hospital drugs. Keep reading...
Dacarbazina®
SEE SmPC >
Dacarbazina<sup>®</sup>
Eptadone®
SEE SmPC >
Eptadone<sup>®</sup>
Gliolan®
SEE SmPC >
Gliolan<sup>®</sup>
NO